Maysun M. Hasan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maysun M. Hasan has a total of 127 co-authors. Here are the top co-authors by number of shared publications:
- Brian R. Houck-Loomis
Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, USA
8 shared publications Fanli Meng
8 shared publicationsHelena A. Yu
8 shared publicationsJason C. Chang
8 shared publicationsAndrew Chow
7 shared publications- Christine Iacobuzio-Donahue
The David M Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY
7 shared publications
Latest Publications
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data1 from ctDNA as a Molecular Biomarker in the Phase II Trial of Imatinib plus Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumor
Representativeness of Study Participants
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data1 from ctDNA as a Molecular Biomarker in the Phase II Trial of Imatinib plus Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumor
Representativeness of Study Participants
- 22 July 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (19) , 4110-4121
ctDNA as a Molecular Biomarker in the Phase II Trial of Imatinib plus Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumor
Purpose: This study investigated factors that affected ctDNA detection and ctDNA as a molecular biomarker in a phase II trial of imatinib and binimetinib in newly diagnosed advanced gastrointestinal stromal tumor, including patients exposed to imatinib within 4 weeks of trial enrollment. Experimental Design: Plasma and tumor tissue samples were collected at baseline, during treatment, and upon progression. DNAs extracted from plasma and tumor tissue were analyzed using genomic assays, Memorial Sloan Kettering Analysis of Circulating cfDNA to Evaluate Somatic Status and Memorial Sloan Kettering Integrated Mutation Profiling of Actionable Cancer Targets, respectively. Sequenced ctDNA detection of the primary oncogenic driver was determined and correlated with clinical characteristics. Results: Patients (n = 31) included in this analysis had KIT mutations (n = 29, 94%) and metastatic disease (n = 24, 77%) and achieved the best response of partial response (n = 22, 71%), stable disease (n = 8, 26%), or progressive disease (n = 1, 3%). Sixteen patients (52%) were exposed to imatinib at baseline. The ctDNA detection rate of the primary oncogenic driver at baseline was 39% (n = 12/31) and was significantly more likely in patients who were treatment-naïve (n = 15) or had ≤4.2 weeks of treatment (n = 8) than in those otherwise (48% vs. 13%; P value = 0.004). Baseline ctDNA detection did not correlate with tumor burden or stage. The ctDNA serial analysis of the primary oncogenic driver paralleled and sometimes preceded radiographic response. ctDNA detected resistance mutations in KIT (n = 4). Active treatment influenced the detection of secondary KIT alterations in one patient. Conclusions: Active therapy at the time of ctDNA collection negatively affected the ability to detect primary and secondary KIT alterations in sequenced ctDNA from patients with advanced gastrointestinal stromal tumor. ctDNA responses may precede radiographic responses and merit further investigation.
- 22 July 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (19) , 4110-4121
ctDNA as a Molecular Biomarker in the Phase II Trial of Imatinib plus Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumor
Purpose: This study investigated factors that affected ctDNA detection and ctDNA as a molecular biomarker in a phase II trial of imatinib and binimetinib in newly diagnosed advanced gastrointestinal stromal tumor, including patients exposed to imatinib within 4 weeks of trial enrollment. Experimental Design: Plasma and tumor tissue samples were collected at baseline, during treatment, and upon progression. DNAs extracted from plasma and tumor tissue were analyzed using genomic assays, Memorial Sloan Kettering Analysis of Circulating cfDNA to Evaluate Somatic Status and Memorial Sloan Kettering Integrated Mutation Profiling of Actionable Cancer Targets, respectively. Sequenced ctDNA detection of the primary oncogenic driver was determined and correlated with clinical characteristics. Results: Patients (n = 31) included in this analysis had KIT mutations (n = 29, 94%) and metastatic disease (n = 24, 77%) and achieved the best response of partial response (n = 22, 71%), stable disease (n = 8, 26%), or progressive disease (n = 1, 3%). Sixteen patients (52%) were exposed to imatinib at baseline. The ctDNA detection rate of the primary oncogenic driver at baseline was 39% (n = 12/31) and was significantly more likely in patients who were treatment-naïve (n = 15) or had ≤4.2 weeks of treatment (n = 8) than in those otherwise (48% vs. 13%; P value = 0.004). Baseline ctDNA detection did not correlate with tumor burden or stage. The ctDNA serial analysis of the primary oncogenic driver paralleled and sometimes preceded radiographic response. ctDNA detected resistance mutations in KIT (n = 4). Active treatment influenced the detection of secondary KIT alterations in one patient. Conclusions: Active therapy at the time of ctDNA collection negatively affected the ability to detect primary and secondary KIT alterations in sequenced ctDNA from patients with advanced gastrointestinal stromal tumor. ctDNA responses may precede radiographic responses and merit further investigation.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from Multiomic Analysis of Lung Tumors Defines Pathways Activated in Neuroendocrine Transformation
Supplemental figures and figure legends.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from Multiomic Analysis of Lung Tumors Defines Pathways Activated in Neuroendocrine Transformation
Supplemental figures and figure legends.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Multiomic Analysis of Lung Tumors Defines Pathways Activated in Neuroendocrine Transformation
Lineage plasticity is implicated in treatment resistance in multiple cancers. In lung adenocarcinomas (LUAD) amenable to targeted therapy, transformation to small cell lung cancer (SCLC) is a recognized resistance mechanism. Defining molecular mechanisms of neuroendocrine (NE) transformation in lung cancer has been limited by a paucity of pre/posttransformation clinical samples. Detailed genomic, epigenomic, transcriptomic, and protein characterization of combined LUAD/SCLC tumors, as well as pre/posttransformation samples, supports that NE transformation is primarily driven by transcriptional reprogramming rather than mutational events. We identify genomic contexts in which NE transformation is favored, including frequent loss of the 3p chromosome arm. We observed enhanced expression of genes involved in the PRC2 complex and PI3K/AKT and NOTCH pathways. Pharmacologic inhibition of the PI3K/AKT pathway delayed tumor growth and NE transformation in an EGFR-mutant patient-derived xenograft model. Our findings define a novel landscape of potential drivers and therapeutic vulnerabilities of NE transformation in lung cancer.Significance:The difficulty in collection of transformation samples has precluded the performance of molecular analyses, and thus little is known about the lineage plasticity mechanisms leading to LUAD-to-SCLC transformation. Here, we describe biological pathways dysregulated upon transformation and identify potential predictors and potential therapeutic vulnerabilities of NE transformation in the lung.See related commentary by Meador and Lovly, p. 2962.This article is highlighted in the In This Issue feature, p. 2945
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Multiomic Analysis of Lung Tumors Defines Pathways Activated in Neuroendocrine Transformation
Lineage plasticity is implicated in treatment resistance in multiple cancers. In lung adenocarcinomas (LUAD) amenable to targeted therapy, transformation to small cell lung cancer (SCLC) is a recognized resistance mechanism. Defining molecular mechanisms of neuroendocrine (NE) transformation in lung cancer has been limited by a paucity of pre/posttransformation clinical samples. Detailed genomic, epigenomic, transcriptomic, and protein characterization of combined LUAD/SCLC tumors, as well as pre/posttransformation samples, supports that NE transformation is primarily driven by transcriptional reprogramming rather than mutational events. We identify genomic contexts in which NE transformation is favored, including frequent loss of the 3p chromosome arm. We observed enhanced expression of genes involved in the PRC2 complex and PI3K/AKT and NOTCH pathways. Pharmacologic inhibition of the PI3K/AKT pathway delayed tumor growth and NE transformation in an EGFR-mutant patient-derived xenograft model. Our findings define a novel landscape of potential drivers and therapeutic vulnerabilities of NE transformation in lung cancer.Significance:The difficulty in collection of transformation samples has precluded the performance of molecular analyses, and thus little is known about the lineage plasticity mechanisms leading to LUAD-to-SCLC transformation. Here, we describe biological pathways dysregulated upon transformation and identify potential predictors and potential therapeutic vulnerabilities of NE transformation in the lung.See related commentary by Meador and Lovly, p. 2962.This article is highlighted in the In This Issue feature, p. 2945
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from Multiomic Analysis of Lung Tumors Defines Pathways Activated in Neuroendocrine Transformation
Supplemental figures and figure legends.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from Multiomic Analysis of Lung Tumors Defines Pathways Activated in Neuroendocrine Transformation
Supplemental figures and figure legends.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Multiomic Analysis of Lung Tumors Defines Pathways Activated in Neuroendocrine Transformation
Lineage plasticity is implicated in treatment resistance in multiple cancers. In lung adenocarcinomas (LUAD) amenable to targeted therapy, transformation to small cell lung cancer (SCLC) is a recognized resistance mechanism. Defining molecular mechanisms of neuroendocrine (NE) transformation in lung cancer has been limited by a paucity of pre/posttransformation clinical samples. Detailed genomic, epigenomic, transcriptomic, and protein characterization of combined LUAD/SCLC tumors, as well as pre/posttransformation samples, supports that NE transformation is primarily driven by transcriptional reprogramming rather than mutational events. We identify genomic contexts in which NE transformation is favored, including frequent loss of the 3p chromosome arm. We observed enhanced expression of genes involved in the PRC2 complex and PI3K/AKT and NOTCH pathways. Pharmacologic inhibition of the PI3K/AKT pathway delayed tumor growth and NE transformation in an EGFR-mutant patient-derived xenograft model. Our findings define a novel landscape of potential drivers and therapeutic vulnerabilities of NE transformation in lung cancer.Significance:The difficulty in collection of transformation samples has precluded the performance of molecular analyses, and thus little is known about the lineage plasticity mechanisms leading to LUAD-to-SCLC transformation. Here, we describe biological pathways dysregulated upon transformation and identify potential predictors and potential therapeutic vulnerabilities of NE transformation in the lung.See related commentary by Meador and Lovly, p. 2962.This article is highlighted in the In This Issue feature, p. 2945
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Multiomic Analysis of Lung Tumors Defines Pathways Activated in Neuroendocrine Transformation
Lineage plasticity is implicated in treatment resistance in multiple cancers. In lung adenocarcinomas (LUAD) amenable to targeted therapy, transformation to small cell lung cancer (SCLC) is a recognized resistance mechanism. Defining molecular mechanisms of neuroendocrine (NE) transformation in lung cancer has been limited by a paucity of pre/posttransformation clinical samples. Detailed genomic, epigenomic, transcriptomic, and protein characterization of combined LUAD/SCLC tumors, as well as pre/posttransformation samples, supports that NE transformation is primarily driven by transcriptional reprogramming rather than mutational events. We identify genomic contexts in which NE transformation is favored, including frequent loss of the 3p chromosome arm. We observed enhanced expression of genes involved in the PRC2 complex and PI3K/AKT and NOTCH pathways. Pharmacologic inhibition of the PI3K/AKT pathway delayed tumor growth and NE transformation in an EGFR-mutant patient-derived xenograft model. Our findings define a novel landscape of potential drivers and therapeutic vulnerabilities of NE transformation in lung cancer.Significance:The difficulty in collection of transformation samples has precluded the performance of molecular analyses, and thus little is known about the lineage plasticity mechanisms leading to LUAD-to-SCLC transformation. Here, we describe biological pathways dysregulated upon transformation and identify potential predictors and potential therapeutic vulnerabilities of NE transformation in the lung.See related commentary by Meador and Lovly, p. 2962.This article is highlighted in the In This Issue feature, p. 2945
- Top Cited PapersOpen Access
- 1 December 2021
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 11 (12) , 3028-3047
Multiomic Analysis of Lung Tumors Defines Pathways Activated in Neuroendocrine Transformation
Lineage plasticity is implicated in treatment resistance in multiple cancers. In lung adenocarcinomas (LUAD) amenable to targeted therapy, transformation to small cell lung cancer (SCLC) is a recognized resistance mechanism. Defining molecular mechanisms of neuroendocrine (NE) transformation in lung cancer has been limited by a paucity of pre/posttransformation clinical samples. Detailed genomic, epigenomic, transcriptomic, and protein characterization of combined LUAD/SCLC tumors, as well as pre/posttransformation samples, supports that NE transformation is primarily driven by transcriptional reprogramming rather than mutational events. We identify genomic contexts in which NE transformation is favored, including frequent loss of the 3p chromosome arm. We observed enhanced expression of genes involved in the PRC2 complex and PI3K/AKT and NOTCH pathways. Pharmacologic inhibition of the PI3K/AKT pathway delayed tumor growth and NE transformation in an EGFR-mutant patient-derived xenograft model. Our findings define a novel landscape of potential drivers and therapeutic vulnerabilities of NE transformation in lung cancer. Significance: The difficulty in collection of transformation samples has precluded the performance of molecular analyses, and thus little is known about the lineage plasticity mechanisms leading to LUAD-to-SCLC transformation. Here, we describe biological pathways dysregulated upon transformation and identify potential predictors and potential therapeutic vulnerabilities of NE transformation in the lung. See related commentary by Meador and Lovly, p. 2962. This article is highlighted in the In This Issue feature, p. 2945
- 1 December 2021
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 11 (12) , 3028-3047
Top Cited PapersOpen AccessMultiomic Analysis of Lung Tumors Defines Pathways Activated in Neuroendocrine Transformation
Lineage plasticity is implicated in treatment resistance in multiple cancers. In lung adenocarcinomas (LUAD) amenable to targeted therapy, transformation to small cell lung cancer (SCLC) is a recognized resistance mechanism. Defining molecular mechanisms of neuroendocrine (NE) transformation in lung cancer has been limited by a paucity of pre/posttransformation clinical samples. Detailed genomic, epigenomic, transcriptomic, and protein characterization of combined LUAD/SCLC tumors, as well as pre/posttransformation samples, supports that NE transformation is primarily driven by transcriptional reprogramming rather than mutational events. We identify genomic contexts in which NE transformation is favored, including frequent loss of the 3p chromosome arm. We observed enhanced expression of genes involved in the PRC2 complex and PI3K/AKT and NOTCH pathways. Pharmacologic inhibition of the PI3K/AKT pathway delayed tumor growth and NE transformation in an EGFR-mutant patient-derived xenograft model. Our findings define a novel landscape of potential drivers and therapeutic vulnerabilities of NE transformation in lung cancer. Significance: The difficulty in collection of transformation samples has precluded the performance of molecular analyses, and thus little is known about the lineage plasticity mechanisms leading to LUAD-to-SCLC transformation. Here, we describe biological pathways dysregulated upon transformation and identify potential predictors and potential therapeutic vulnerabilities of NE transformation in the lung. See related commentary by Meador and Lovly, p. 2962. This article is highlighted in the In This Issue feature, p. 2945
- Top Cited PapersOpen Access
- 18 June 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-12
Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS
Circulating cell-free DNA from blood plasma of cancer patients can be used to non-invasively interrogate somatic tumor alterations. Here we develop MSK-ACCESS (Memorial Sloan Kettering - Analysis of Circulating cfDNA to Examine Somatic Status), an NGS assay for detection of very low frequency somatic alterations in 129 genes. Analytical validation demonstrated 92% sensitivity in de-novo mutation calling down to 0.5% allele frequency and 99% for a priori mutation profiling. To evaluate the performance of MSK-ACCESS, we report results from 681 prospective blood samples that underwent clinical analysis to guide patient management. Somatic alterations are detected in 73% of the samples, 56% of which have clinically actionable alterations. The utilization of matched normal sequencing allows retention of somatic alterations while removing over 10,000 germline and clonal hematopoiesis variants. Our experience illustrates the importance of analyzing matched normal samples when interpreting cfDNA results and highlights the importance of cfDNA as a genomic profiling source for cancer patients.
- 18 June 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-12
Top Cited PapersOpen AccessEnhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS
Circulating cell-free DNA from blood plasma of cancer patients can be used to non-invasively interrogate somatic tumor alterations. Here we develop MSK-ACCESS (Memorial Sloan Kettering - Analysis of Circulating cfDNA to Examine Somatic Status), an NGS assay for detection of very low frequency somatic alterations in 129 genes. Analytical validation demonstrated 92% sensitivity in de-novo mutation calling down to 0.5% allele frequency and 99% for a priori mutation profiling. To evaluate the performance of MSK-ACCESS, we report results from 681 prospective blood samples that underwent clinical analysis to guide patient management. Somatic alterations are detected in 73% of the samples, 56% of which have clinically actionable alterations. The utilization of matched normal sequencing allows retention of somatic alterations while removing over 10,000 germline and clonal hematopoiesis variants. Our experience illustrates the importance of analyzing matched normal samples when interpreting cfDNA results and highlights the importance of cfDNA as a genomic profiling source for cancer patients.